Their are many new HCPCS level II codes will be used effectively 1st April 2024. Also, you will get to see some changes or revision on some codes from April 2024. With some additions and revision their are some deletion of codes as well which will not be used after 1st April 2024.
These all are the quarterly updates about HCPCS codes by CMS. The Medical coders have to follow the new updates and used codes accordingly to get paid for all the services provided based on the documentation.
New HCPCS Codes (effective 1st April 2024)
- G0138, intravenous infusion of cipaglucosidase alfaatga, including provider/supplier acquisition and clinical supervision of oral administration of miglustat in preparation of receipt of cipaglucosidase alfa-atga
- J0177, injection, aflibercept hd, 1 mg
- J0209, injection, sodium thiosulfate (hope), 100 mg
- J0577, injection, buprenorphine extendedrelease (brixadi), less than or equal to 7 days of therapy
- J0578, injection, buprenorphine extendedrelease (brixadi), greater than 7 days of therapy
- J0589, injection, daxibotulinumtoxina-lanm, 1 unit
- J0650, injection, levothyroxine sodium, not otherwise specified, 10 mcg
- J0651, injection, levothyroxine sodium (fresenius kabi) not therapeutically equivalent to J0650, 10 mcg
- J0652, injection, levothyroxine sodium (hikma) not therapeutically equivalent to J0650, 10 mcg
- J1010, injection, methylprednisolone acetate, 1 mg
- J1202, Miglustat, oral, 65 mg
- J1203, injection, cipaglucosidase alfa-atga, 5 mg
- J1323, injection, elranatamab-bcmm, 1 mg
- J1434, injection, fosaprepitant (focinvez), 1 mg
- J2277, injection, motixafortide, 0.25 mg
- J2782, injection, avacincapted pegol, 0.1 mg
- J2801, injection, risperidone (rykindo), 0.5 mg
- J2919, injection, methylprednisolone sodium succinate, 5 mg
- J3055, injection, talquetamab-tgvs, 0.25 mg
- J3424, injection, hydroxocobalamin, intravenous, 10 grams
- J7165, injection, prothrombin complex concentrate, human-lans, per i.u. of factor ix activity
- J7354, Cantharidin for topical administration, 0.7%, single unit dose applicator (3.2 mg)
- J9073, injection, cyclophosphamide (ingenus), 5 mg
- J9074, injection, cyclophosphamide (sandoz), 5 mg
- J9075, injection, cyclophosphamide, not otherwise specified, 5mg
- J9248, injection, melphalan (hepzato), 1 mg
- J9249, injection, melphalan (apotex), 1 mg
- J9376, injection, pozelimab-bbfg, 1 mg
- Q4305, American amnion ac tri-layer, per square centimeter
- Q4306, American amnion ac, per square centimeter
- Q4307, American amnion, per square centimeter
- Q4308, Sanopellis, per square centimeter
- Q4309, Via matrix, per square centimeter
- Q4310, Procenta, per 100 mg
- Q5133, injection, tocilizumab-bavi (tofidence), biosimilar, 1 mg
- Q5134, injection, natalizumab-sztn (tyruko), biosimilar, 1 mg
Revised HCPCS codes (effective 1st April 2024)
J0208 injection, sodium thiosulfate (pedmark), 100 mg
J0612 injection, calcium gluconate, not otherwise specified, 10 mg
J0613 injection, calcium gluconate (wg critical care) not therapeutically equivalent to J0612, 10 mg
J3380 injection, vedolizumab, intravenous, 1 mg
Deleted HCPCS codes (effective 1st April 2024)
- C9159, injection, prothrombin complex concentrate (human), balfaxar, per i.u. of factor ix activity
- C9160, injection, daxibotulinumtoxina-lanm, 1 unit
- C9161, injection, aflibercept hd, 1 mg
- C9162, injection, avacincaptad pegol, 0.1 mg
- C9163, injection, pozelimab-bbfg, 1 mg
- C9164, Cantharidin for topical administration, 0.7%, single unit dose applicator (3.2 mg)
- C9165, injection, elranatamab-bcmm, 1 mg
- J0576, injection, buprenorphine extended-release (brixadi), 1 mg
- J1020, injection, methylprednisolone acetate, 20 mg
- J1030, injection, methylprednisolone acetate, 40 mg
- J1040, injection, methylprednisolone acetate, 80 mg
- J1840, injection, kanamycin sulfate, up to 500 mg
- J1850, injection, kanamycin sulfate, up to 75 mg
- J2920, injection, methylprednisolone sodium succinate, up to 40 mg
- J2930, injection, methylprednisolone sodium succinate, up to 125 mg
- J9070, Cyclophosphamide, 100 mg
- J9250, Methotrexate sodium, 5 mg
- Q4244, Procenta, per 200 mg
Reference :
